Ticker

BioAtla, Inc. (NASDAQ: BCAB - Get Free Report) saw a large decrease in short interest in the month of February. As of February 13th, there was short interest totaling 2,697,341 shares, a decrease of 59.2% from the January 29th total of 6,612,587 shares. Currently, 4.8% of the company's shares are short sold. Based on an average

Shares of BioAtla, Inc. (NASDAQ: BCAB - Get Free Report) have earned an average recommendation of "Hold" from the five ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has assigned a buy recommendation to the

SAN DIEGO, Dec. 31, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, and GATC Health Corp. (GATC), a tech-bio company leveraging artificial intelligence (AI) to transform drug discovery and development, today announced a SPV transaction to…

BioAtla, Inc. (NASDAQ: BCAB - Get Free Report) saw a significant decline in short interest during the month of December. As of December 15th, there was short interest totaling 4,341,741 shares, a decline of 29.9% from the November 30th total of 6,190,599 shares. Based on an average trading volume of 989,384 shares, the short-interest ratio is

Mirum Pharmaceuticals (NASDAQ: MIRM - Get Free Report) and BioAtla (NASDAQ: BCAB - Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership. Institutional and Insider Ownership 77.2% of BioAtla shares are